Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. EMEA Innovative Medicine /
    2. Janssen Announces European Commission Approval for Expanded Use of Erleada®▼ (apalutamide) for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Janssen Announces European Commission Approval for Expanded Use of Erleada®▼ (apalutamide) for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Janssen Announces European Commission Approval for Expanded Use of Erleada®▼ (apalutamide) for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer